Just last year, Erik Lefkofsky started a technology company that focused on an operating system to fight against cancer. This company came to be known as Tempest. About 40 percent of adults in the U.S. end up facing a cancer diagnosis. This is an astronomical number, and it is only going up year after year. Luckily, there are companies like Tempest out there working to increase the survival rates of those who have been diagnosed.
One characteristic of Tempest is that they have changed the focus. Instead of simply attempting to apply the same treatment to everyone with this disease, they understand that cancer isn’t that simple. Their goal is not to apply the same exact treatment to every patient, but personalize it to fit the needs of the individual by gathering their molecular and clinical data.
A major hurdle that this company has faced in their research attempts has been the costs of data analysis. Gathering certain information has definitely been a struggle. The cost of their research in 2003 was about $100 million. Thankfully, technology is advancing and the costs have been reduced drastically since then. Since so much research has been done already, this should drive the cost even lower.
Erik Lefkofsky is one of the most inspirational people of our time, and definitely doesn’t get enough credit for it. He has donated millions of dollars to cancer research and knows his way around the business world. His ventures into Groupon, ECHO, and Uptake are just small examples of his character. The fact that he has co-founded so many companies shows that although he has already found success, he is going to continue working hard for a cause larger than only himself.
The reason he founded Tempest was to jump-start cancer research and take a different approach. His plans for Tempest would include ,”analyzing a patient’s genetic code in the context of molecular therapies,” in his own words, as well as modernizing cancer treatment. The results in his investment of time, money and energy have shown to be successful. Tempest is working with patients that have different types of cancer and has already helped doctors provide better personalized care to patients according to their individual needs.